Appendix 3Y - Dr Daniel Tillett
Released
Released
Announcement PDF
Racura Oncology Ltd | ABN 61 149 318 749 | L36 1 Macquarie Place Sydney NSW 2000 Australia
+61 2 8051 3043 | info@racuraoncology.com | www.racuraoncology.com 1
ASXAnnouncement
Appendix 3Y
Change of Director’s Interest Notice
Dr Daniel Tillett
23 September 2026
This notice reflects the on-market sale of RAC shares held personally by Dr Tillett and the purchase of RAC
shares on-market by Nucleics Pty Ltd, a corporate entity sole owned and controlled by Dr Tillett. Dr Tillett
has undertaken this change for personal estate and tax planning purposes.
The sale and purchase transfer process remains ongoing. Once completed, Dr Tillett’s total interest in
Racura Oncology will remain unchanged on a combined direct and indirect basis.
-ENDS-
Racura Oncology Ltd | ABN 61 149 318 749 | L36 1 Macquarie Place Sydney NSW 2000 Australia
+61 2 8051 3043 | info@racuraoncology.com | www.racuraoncology.com 2
About Racura Oncology
Racura Oncology (ASX: RAC) is a Phase 3 clinical-stage biopharmaceutical company with a mission to
silence cancer.
Racura’s lead asset, (E,E)-bisantrene, is a clinically derisked small-molecule anticancer agent that
primarily acts by stabilising G4-DNA and RNA structures, driving potent silencing of c-MYC, a key cancer
gene dysregulated in up to 70% of all cancers. (E,E)-bisantrene has shown therapeutic activity in cancer
patients and has a well-characterised safety profile. Racura’s discoveries have supported composition-of-
matter IP filings that, if granted, could provide up to 20 years of patent protection for (E,E)-bisantrene.
Racura is advancing RC220, its proprietary formulation of (E,E)-bisantrene, to address significant unmet
need across multiple MYC-driven oncology indications. The Company’s clinical programs include the EMILI
Phase 3 trial in acute myeloid leukaemia, the HARNESS Phase 1a/b trial in combination with osimertinib
for EGFR-mutated non-small cell lung cancer, and the CPACS Phase 1a/b trial in combination with
doxorubicin, where Racura aims to deliver both anthracycline cardioprotection and enhanced anticancer
activity.
Racura has collaborated with Astex, Emory University, Purdue University, MD Anderson Cancer Center,
Sheba Medical Center, University of North Carolina School of Medicine, University of Wollongong, and the
University of Newcastle. Racura is actively exploring partnerships, licence agreements, and potential
commercial merger and acquisition opportunities to accelerate global patient access to RC220.
Learn more at www.racuraoncology.com.
For questions about this announcement or previous Racura Oncology announcements, please visit our
Interactive Announcements page.
Racura encourages our investors to go paperless by registering their email details with the Company’s
share registry, Automic Registry Services, at www.automicgroup.com.au.
Release authorised by Media Contact
Daniel Tillett, CEO Cherie Hartley +61 418 737 020
info@racuraoncology.com cherie.hartley@irdepartment.com.au
Appendix 3Y
Change of Director’s Interest Notice
+ See chapter 19 for defined terms.
Appendix 3Y Page 1
Rule 3.19A.2
Appendix 3Y
Change of Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and
documents given to ASX become ASX’s property and may be made public.
Introduced 30/9/2001.
Name of entity Racura Oncology Limited
ABN 61 149 318 749
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the
director for the purposes of section 205G of the Corporations Act.
Name of Director Daniel Tillett
Date of last notice 28 May 2026
Part 1 - Change of director’s relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be
disclosed in this part.
Direct or indirect interest 1. Direct
2. Indirect
Nature of indirect interest
(including registered holder)
Note: Provide details of the circumstances
giving rise to the relevant interest.
2. Nucleics Pty Ltd – Daniel Tillett is sole director and sole
shareholder.
Date of change 16, 17, 18, 21 & 22 September 2026
No. of securities held prior
to change
1. 20,269,351 fully paid ordinary shares
1,534,712 options exercisable at $1.45, expiring 29/11/2028
3,061,101 options exercisable at $4.25, expiring 29/11/2028
432,680 options exercisable at $1.67, expiring 30/6/2029
Class Fully paid ordinary shares
Number acquired 1. 4,500
2. 80,000
Number disposed 1. 89,500
Appendix 3Y
Change of Director’s Interest Notice
+ See chapter 19 for defined terms.
Appendix 3Y Page 2
Value/Consideration
includes brokerage/gst
Note: If consideration is non-cash, provide
details and estimated valuation
$172,166.39 - purchases
$179,716.56 - sales
No. of securities held after
change
1. 20,184,351 fully paid ordinary shares
1,534,712 options exercisable at $1.45, expiring 29/11/2028
3,061,101 options exercisable at $4.25, expiring 29/11/2028
432,680 options exercisable at $1.67, expiring 30/6/2029
2. 80,000 fully paid ordinary shares
Nature of change
Example: on-market trade, off-market trade,
exercise of options, issue of securities under
dividend reinvestment plan, participation in
buy-back
On-market purchases and sales for estate planning and tax
planning purposes.
Part 2 – Change of director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be
disclosed in this part.
Detail of contract N/A
Nature of interest N/A
Name of registered holder
(if issued securities)
N/A
Date of change N/A
No. and class of securities to
which interest related prior to
change
Note: Details are only required for a contract in relation
to which the interest has changed
N/A
Interest acquired N/A
Interest disposed N/A
Value/Consideration
Note: If consideration is non-cash, provide details and an
estimated valuation
N/A
Interest after change N/A
Part 3 – +Closed period
Were the interests in the securities or contracts detailed
above traded during a +closed period where prior written
clearance was required?
No.
If so, was prior written clearance provided to allow the trade
to proceed during this period?
N/A
If prior written clearance was provided, on what date was this
provided?
N/A
Share your feedback
Discover